Chengdu Antejin Biotechnology

Chengdu Antejin Biotechnology is a Chinese biopharmaceutical company focused on the development and commercialization of innovative human vaccines. Established in 2012 and headquartered in Chengdu, the company specializes in advanced technology platforms including polysaccharide-protein conjugation and recombinant protein expression. Antejin was acquired by Walvax Biotechnology to strengthen its position in the global vaccine market, particularly for high-demand products like the 13-valent pneumococcal conjugate vaccine. Its pipeline features late-stage candidates for pneumococcal disease, meningococcal meningitis, and rabies, alongside early-stage programs for HPV. The company maintains large-scale, GMP-compliant manufacturing facilities designed to meet both domestic and international regulatory standards. Antejin aims to improve public health by providing high-quality, accessible immunization solutions.